3 Penny Stocks to Watch Now, 8/14/25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Source: TipRanks
Penny Stocks to Watch: Momentus, X4 Pharmaceuticals, and ReShape Lifesciences are highlighted as top penny stocks based on their significant Dollar Volume and recent stock price surges, with Momentus experiencing a 72% increase after a NASA contract announcement.
Company Developments: X4 Pharmaceuticals secured an $85 million private placement to support its drug development, while ReShape Lifesciences' shares rose 57.6% following the approval of its merger with Vyome Therapeutics, set to trade under a new name.
Analyst Views on XFOR
Wall Street analysts forecast XFOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XFOR is 57.75 USD with a low forecast of 7.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.620
Low
7.00
Averages
57.75
High
120.00
Current: 3.620
Low
7.00
Averages
57.75
High
120.00
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
